Josiane Pillonel1, Camille Pelat2, Pierre Tiberghien3, Claire Sauvage1, Bruno Danic4, Christophe Martinaud5, Francis Barin6, Isabelle Sainte-Marie7, Bruno Coignard1, Sylvie Gross3, Syria Laperche8, Florence Lot1. 1. Santé publique France, Direction des Maladies Infectieuses, Saint-Maurice, France. 2. Santé publique France, Direction Appui, Traitements et Analyses de données, Saint-Maurice, France. 3. Etablissement Français du Sang, La Plaine Saint-Denis, France. 4. Etablissement Français du Sang de Bretagne, Rennes, France. 5. Centre de Transfusion Sanguine des Armées, Clamart, France. 6. CHU Bretonneau & Université François Rabelais, Centre National de Référence du VIH-Laboratoire associé, Inserm U1259, Tours, France. 7. Agence Nationale de Sécurité du Médicament et des produits de santé, Saint-Denis, France. 8. Centre National de Référence Risques Infectieux Transfusionnels, Institut National de Transfusion Sanguine (INTS), Paris, France.
Abstract
BACKGROUND: Blood donation deferral for men who have sex with men (MSM) in France was reduced from permanent to 12 months in July 2016. To inform a further reduction of the deferral period, an HIV risk assessment was conducted with two scenarios: S1, 4-month deferral; S2, 4-month deferral only in the case of more than one sexual partner (i.e., similar to other blood donors). METHODS: Baseline HIV residual risk (RR) was calculated from July 2016 to December 2017, using the Incidence Rate-Window Period method. The impact of both scenarios on RR was assessed using data from surveys on MSM and blood donors, to estimate 1) the number of additional MSM expected to donate in each scenario and 2) HIV incidence among these donors. RESULTS: Baseline HIV RR was estimated at 1 in 6,380,000 donations. For S1, an additional 733 MSM donors, and an additional 0.09 HIV-positive donations were estimated, yielding an unchanged RR of 1 in 6,300,000. For S2, these numbers were estimated at 3102 and 3.92, respectively, yielding an RR of 1 in 4,300,000. Sensitivity analyses showed that, under worst-case assumptions, the RR would equal 1 in 6,225,000 donations for S1 and 1 in 3,000,000 for S2. CONCLUSION: For both scenarios, the HIV RR remains very low. For S1, the risk is identical to the baseline RR. For S2, it is 1.5 times higher, and sensitivity analysis shows that this estimate is less robust than for S1. The French Minister of Health announced that S1 will be implemented in April 2020.
BACKGROUND: Blood donation deferral for men who have sex with men (MSM) in France was reduced from permanent to 12 months in July 2016. To inform a further reduction of the deferral period, an HIV risk assessment was conducted with two scenarios: S1, 4-month deferral; S2, 4-month deferral only in the case of more than one sexual partner (i.e., similar to other blood donors). METHODS: Baseline HIV residual risk (RR) was calculated from July 2016 to December 2017, using the Incidence Rate-Window Period method. The impact of both scenarios on RR was assessed using data from surveys on MSM and blood donors, to estimate 1) the number of additional MSM expected to donate in each scenario and 2) HIV incidence among these donors. RESULTS: Baseline HIV RR was estimated at 1 in 6,380,000 donations. For S1, an additional 733 MSM donors, and an additional 0.09 HIV-positive donations were estimated, yielding an unchanged RR of 1 in 6,300,000. For S2, these numbers were estimated at 3102 and 3.92, respectively, yielding an RR of 1 in 4,300,000. Sensitivity analyses showed that, under worst-case assumptions, the RR would equal 1 in 6,225,000 donations for S1 and 1 in 3,000,000 for S2. CONCLUSION: For both scenarios, the HIV RR remains very low. For S1, the risk is identical to the baseline RR. For S2, it is 1.5 times higher, and sensitivity analysis shows that this estimate is less robust than for S1. The French Minister of Health announced that S1 will be implemented in April 2020.
Authors: Eduard Grebe; Michael P Busch; Edward P Notari; Roberta Bruhn; Claire Quiner; Daniel Hindes; Mars Stone; Sonia Bakkour; Hong Yang; Phillip Williamson; Debra Kessler; Rita Reik; Susan L Stramer; Simone A Glynn; Steven A Anderson; Alan E Williams; Brian Custer Journal: Blood Date: 2020-09-10 Impact factor: 22.113
Authors: Elisabeth Vesnaver; Mindy Goldman; Sheila O'Brien; Paul MacPherson; Terrie Butler-Foster; Don Lapierre; Joanne Otis; Dana V Devine; Marc Germain; Andrew Rosser; Richard MacDonagh; Taylor Randall; William Osbourne-Sorrell; Broderic Clement-Thorne; Taim Bilal Al-Bakri; Kyle A Rubini; Nolan E Hill; Justin Presseau Journal: Health Res Policy Syst Date: 2020-11-02